{"id":"W2335244965","doi":"10.1200/jco.2007.25.18_suppl.14018","title":"A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in combination with full-dose cetuximab in patients (pts) with advanced gastrointestinal malignancies (AGM) who failed prior therapy","year":2007,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Cetuximab; Internal medicine; Tyrosine-kinase inhibitor; Oncology; Irinotecan; Urology; Pharmacokinetics; Pharmacology; Colorectal cancer; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001190662,0.001922044,0.002083612,0.0006145979,0.0004615001,0.001055171,0.001168181,0.001350533,0.003488531],"category_scores_gemma":[0.001000339,0.001023705,0.001240446,0.0004883017,0.001386628,0.001077985,0.0004011081,0.003792585,0.001094023],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001115514,"about_ca_system_score_gemma":0.001653493,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001154113,"about_ca_topic_score_gemma":0.002636042,"domain_scores_codex":[0.9995946,0.0001813511,0.00001766386,0.00007981723,0.00004171745,0.00008488563],"domain_scores_gemma":[0.9992519,0.0001224921,0.0001288838,0.00005958428,0.00004214755,0.0003949427],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6411316,0.1754504,0.005338619,0.0009685474,0.001207827,0.0006336992,0.0006126171,0.003569479,0.08584975,0.0003615441,0.004578326,0.08029763],"study_design_scores_gemma":[0.4326542,0.5520765,0.008105071,0.00002147467,0.0003240824,0.0003399897,0.0000592591,0.001125541,0.003569997,0.000135197,0.001557572,0.00003107175],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946567,0.0009925246,0.0004269664,0.0003209327,0.0001121005,0.001481509,0.0004999079,0.00009293224,0.001416496],"genre_scores_gemma":[0.9897144,0.001586819,0.001476427,0.0006458581,0.0002555479,0.001795394,0.001726406,0.0000366737,0.002762382],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003488531,"threshold_uncertainty_score":0.01167035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04923117680282855,"score_gpt":0.3980623160294409,"score_spread":0.3488311392266123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}